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Introduction: 5-alpha reductase inhibitors can reduce the risk of prostate cancer (PCa)
but can be associated with significant side effects. A library of nomograms which predict
the risk of clinical endpoints relevant to dutasteride treatment may help determine if
chemoprevention is suited to the individual patient.Methods: Data from the REDUCE trial
was used to identify predictive factors for 9 endpoints relevant to dutasteride treatment.
Using the treatment and placebo groups from the biopsy cohort, Cox proportional hazards
(PH) and competing risks regression (CRR) models were used to build 18 nomograms,
whose predictive ability was measured by concordance index (CI) and calibration plots.
Results: A total of 18 nomograms assessing the risks of cancer, high grade cancer,
high grade prostatic intraepithelial neoplasia (HGPIN), atypical small acinar proliferation
(ASAP), erectile dysfunction (ED), acute urinary retention (AUR), gynecomastia, urinary
tract infection (UTI) and BPH-related surgery either on or off dutasteride were created.
The nomograms for cancer, high grade cancer, ED, AUR, and BPH-related surgery
demonstrated good discrimination and calibration while those for gynecomastia, UTI,
HGPIN, and ASAP predicted no better than random chance. Conclusions: To aid
patients in determining whether the benefits of dutasteride use outweigh the risks, we
have developed a comprehensive metagram that can generate individualized risks of 9
outcomes relevant to men considering chemoprevention. Better models based on more
predictive markers are needed for some of the endpoints but the current metagram
demonstrates potential as a tool for patient counseling and decision-making that is
accessible, intuitive, and clinically relevant.
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INTRODUCTION
Contemporary management of prostate cancer (PCa) has
revolved around the early detection of disease achieved through
prostate specific antigen (PSA) screening. This paradigm has
led to favorable changes in the epidemiology of PCa, includ-
ing a downward stage migration, increased rates of cure with
definitive treatment, and a reduction in cancer-specific mor-
tality (Catalona et al., 1993; Horner et al., 2009). However,
PCa remains a disease that can inflict significant morbidity
and mortality; indeed, it is still the second leading cause of
cancer death in American men behind lung cancer in 2010
(National Cancer Institute, 2011). On the other hand, there
is evidence that widespread PSA testing has led to an over-
diagnosis and overtreatment of clinically insignificant disease,
unnecessarily exposing men to treatment-related morbidity as
well as incurring significant healthcare costs (Bill-Axelson et al.,
2005; Welch and Albertsen, 2009). As a result, there has been
growing interest in reducing a man’s risk of developing PCa
through chemoprevention and potentially avoiding these prob-
lems altogether.
In the last several years, data from studies assessing the effects
of 5-alpha reductase inhibitors (5-ARI) have demonstrated sig-
nificant benefits in the form of a 23 to 25% reduction in
cancer risk as well as improvement of benign prostatic hyper-
plasia (BPH) related urinary symptoms (Thompson et al., 2003;
Andriole et al., 2010). These findings have suggested a role
for such drugs as chemoprevention in men at risk for devel-
oping PCa. However, treatment with 5-ARIs can be associated
with significant side effects that may adversely impact quality of
life and lead to discontinuation of the drug. For example, data
from the Reduction by Dutasteride of Prostate Cancer Events
(REDUCE) trial showed a significantly higher risk of sexual side
effects, including loss of libido and erectile dysfunction (ED),
as well as an increased incidence of gynecomastia and cardiac
failure.
Therefore, the decision to initiate chemoprevention should
not be taken lightly nor should it be applied indiscriminately
to all men. With multiple clinical endpoints to consider, the
process of calculating an individual man’s risk-to-benefit ratio
regarding 5-ARI treatment can be difficult for both physician
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and patient in the absence of a formalized system to pre-
dict risk. We have previously proposed a novel prediction
tool, dubbed the “metagram,” that can facilitate decision-
making by obviating physicians and patients from having to
predict outcomes themselves or make complex calculations
(Nguyen and Kattan, 2009). Such a comprehensive prediction
tool would incorporate nomograms that can generate indi-
vidualized predictions of all outcomes relevant to the clinical
question and present the data in a manner that is easy to
interpret.
Using data from the REDUCE trial that assessed the effects
of dutasteride in men at high risk of PCa, we have constructed
nomograms that predict the risks of nine clinically relevant end-
points in the absence or presence of dutasteride treatment. The
nomograms have been incorporated into an online metagram
program that can generate personalized predictions of the poten-
tial consequences of dutasteride treatment. Armed with such
data, the individual patient can then make an informed deci-
sion regarding whether chemoprevention with a 5-ARI is right
for him.
MATERIALS AND METHODS
Data from 6729 patients from the REDUCE trial who had at
least one biopsy or prostate surgery were included in this study
(Andriole et al., 2010). This cohort was split into two sub-groups:
(1) patients who received dutasteride (N = 3305) and (2) patients
who received placebo (N = 3424).
Endpoints related to pathology, BPH, and drug-related
side effects were studied (Table 1). The pathological end-
points included PCa, high grade prostate cancer (HGPCa) that
was defined as Gleason score sum ≥7, high grade prostatic
intraepithelial neoplasia (HGPIN), and atypical small acinar
proliferation (ASAP). In this study, HGPIN was counted as an
independent endpoint only if there was no previous or concurrent
ASAP or PCa. Similarly, ASAP was counted only in the absence of
PCa. The endpoints related to BPH measured the risks of acute
urinary retention (AUR), BPH-related surgery, and urinary tract
infection (UTI). The endpoints assessing the side effect profile of
dutasteride included ED and gynecomastia.
Predictive variables for each endpoint were selected by clin-
ical relevance based on findings from the initial publication of
the REDUCE trial (Table 1). Restricted cubic splines were imple-
mented for continuous or ordinal variables to accommodate
potential non-linear relationships. Multivariable analyses were
then performed to measure the correlation between each variable
and the outcome of interest.
For 7 of the 9 endpoints, Cox proportional hazards (PH)
regression models were built from both patient sub-groups.
For HGPIN and ASAP, two separate competing risks regression
(CRR) models were used to investigate the cause-specific cumu-
lative incidence of these endpoints. These Cox PH models and
CRR models served as the basis of nomograms that would be
used to predict each of the 9 outcomes. The discrimination of
each model was quantified by calculating the concordance index
(CI), which is identical to the non-parametric area under the
receiver operating characteristic curve (AUC) in a binary set-
ting, and modified to fit for time-to event or competing risks
outcomes. All models were internally validated using resampling
techniques: bootstrapping analysis with 1000 resamples for the
Cox PH models and 10-fold cross-validation for the CRR mod-
els (to correct for over-fitting bias). In addition, cause-specific
cumulative incidences of HGPIN or ASAP and probabilities of
freedom from the other 7 endpoints were calculated for each of
the models.
Calibration plots for each nomogram were plotted to
measure how closely the predicted risk generated by the model
Table 1 | Predictor variables included in each nomogram.
PCa HGPCa ED AUR BPH Gyn UTI HGPIN ASAP
Age * * * * * * – * *
Prostate volume * * – * * – – * *
No. of biopsy cores * * – – – – – * *
PSA * * – * * – – * *
% free PSA * * – – – – – * *
Family history PCa * * – – – – – * *
DRE * * – – – – – * *
Body mass index * * – – – * – * *
IPSS score – – – * * – – – –
Qmax – – – * * – * – –
Residual volume – – – * * – * – –
Sexually active – – * – – – – – –
History lack of libido – – * – – – – – –
History impotence – – * – – – – – –
PCa, prostate cancer; HGPCa, high-grade prostate cancer; ED, erectile dysfunction; AUR, acute urinary retention; BPH, benign prostatic hyperplasia; Gyn, gyneco-
mastia; UTI, urinary tract infection; HGPIN, high-grade prostatic intraepithelial neoplasia; ASAP, atypical glands suspicious for carcinoma; DRE, digital rectal
examination; IPSS, international prostate symptom score.
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approximated observed rates of the endpoint of interest. A predic-
tion tool that is perfectly calibrated should demonstrate a 1:1 rela-
tionship between predicted and actual outcomes, resulting in a
calibration plot with a 45◦ slope. Calibration was assessed visually
by dividing patients into quartiles of the nomogram-predicted
probabilities of freedom from event (or cumulative incidences
of HGPIN or ASAP), and then plotting the mean predicted
values against Kaplan-Meier estimated probabilities (or non-
parametrically estimated cumulative incidences of HGPIN or
ASAP) for each quartile.
All p-values were generated by two-sided statistical tests, with
a level of 0.05 indicating significance. All statistical analyses were
performed using R software version 2.11.0 (R Development Core
Team, 2010) with the Design and cmprsk libraries added.
RESULTS
The characteristics of the placebo and dutasteride cohorts
appeared to be comparable with no significant differences among
any of the variables used as predictive markers in nomogram
construction (Table 2). The results of the multivariable analyses
assessing the predictive value of the clinical variables for each
Table 2 | Patient characteristics.
Placebo Dutasteride P-value
Number of patients 3424 3305 –
Age (years) 62.7 62.8 0.44272
Prostate volume (cc) 45.5 45.7 0.57712
Number of biopsy cores (mean) 8.7 8.8 0.37677
PSA (ng/dl) 5.9 5.9 0.75824
% free PSA 16.7 16.7 0.85107
BMI (kg/m2) 27.3 27.3 0.87295
IPSS score 8.5 8.6 0.31229
Qmax (mL/sec) 15.3 15.2 0.90313
Residual volume (mL) 46.2 47 0.49068
Family history of PCa
No 2987 2853 0.32667
Yes 437 448
DRE
Abnormal 132 125 0.86863
Normal 3284 3176
Ethnicity
Non-white 295 277 0.73033
White 3129 3028
Sexually active
No 615 621 0.37376
Yes 2807 2680
History of lack of libido
No 2657 2569 0.8489
Yes 751 718
History of impotence
No 2505 2351 0.07281
Yes 902 934
BMI, body mass index; IPSS, international prostate symptom score; Qmax,
maximum flow rate; PCa, prostate cancer; DRE, digital rectal exam.
of the 9 endpoints for both the placebo and dutasteride cohorts
are summarized in Table 3. It should be noted that some of
the endpoints lacked any significantly predictive markers. For
example, the variables of age and body mass index were not pre-
dictive of the risk of gynecomastia in either placebo or dutasteride
groups on multivariable analysis. In the cases of BPH-related
outcomes, markers that were significantly associated with the
outcome in the placebo group (e.g., maximal urinary flow rate
or prostate volume) were no longer predictive in the dutasteride
group.
The concordance indices for the component nomograms are
summarized in Table 4. Several of the nomograms (e.g., those
for UTI, gynecomastia, HGPIN, ASAP) demonstrate poor dis-
crimination and are based on those models that contained a
large proportion of non-predictive variables. Values of less than
0.5 reflect poor discrimination by a given nomogram and are
an artifact of random assignment of risk scores to patients. If
a greater number of cross-validations were to be run, the aver-
age predictive accuracy would likely be closer to 0.5. For the
final metagram, these suboptimal nomograms were replaced by
the overall cumulative incidence probabilities of the endpoint in
question.
Nomogram calibration appeared to correlate with how well
the particular nomogram discriminated. The 4 nomogram pairs
that predict UTI, gynecomastia, ASAP, and HGPIN demon-
strated poor correlation between observed and expected out-
comes, while those nomograms predicting any cancer, high grade
cancer, ED, AUR, or BPH-related surgery demonstrated excellent
calibration.
The component nomograms were then incorporated
into the final metagram, which has been made available
as an online calculator (http://rcc.simpal.com/RCEval.cgi?
RCID=eU9iCH) that can be used by physician or patient to gen-
erate personalized predictions of all 9 endpoints simultaneously
(Figure 1).
DISCUSSION
Despite better understanding of its biology, improved screening
tests, and availability of more efficacious therapy, PCa can still
be associated with significant morbidity and mortality, partic-
ularly if found at an advanced stage. As such, there has been
growing interest in modifying a man’s risk of developing PCa
through chemoprevention with drugs that alter the hormonal
milieu of prostatic cells. Inhibitors of 5-alpha reductase, such as
dutasteride, have been shown to reduce the risk of PCa by nearly
25% but are not without side effects. Consequently, assessing the
balance between benefit and harm associated with dutasteride
treatment is a critical aspect of counseling the patient considering
chemoprevention.
In order to make informed decisions and reduce the risk of
treatment regret, patients require unbiased, evidence-based data
regarding probabilities of treatment success and complications.
A formalized system that is easy to use and interpret and that
can generate accurate tailored predictions can be useful to both
patient and physician. We believe that a metagram, a compre-
hensive prediction software which incorporates highly accurate
nomograms for each endpoint, is best suited to this purpose.
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Table 3 | Hazard ratios and P-values from multivariate analysis.
Variables Placebo Dutasteride
HR Lower 0.95 Upper 0.95 P-value HR Lower 0.95 Upper 0.95 P-value
Prostate cancer
Age 1.6175 1.4411 1.8155 <0.0001 1.5645 1.3712 1.7851 <0.0001
Prostate volume 0.7656 0.6917 0.8473 <0.0001 0.7343 0.6465 0.8341 <0.0001
No. of biopsy cores 0.8462 0.733 0.9769 0.0548∗ 0.8443 0.716 0.9954 0.004
PSA 1.1612 1.0283 1.3113 0.0088 1.1269 0.9837 1.291 0.1998
% free PSA 0.7177 0.6471 0.7958 <0.0001 0.7539 0.6721 0.8456 <0.0001
BMI 0.9932 0.902 1.0935 0.496 1.0504 0.9405 1.1731 0.3806
Family history PCa 1.5439 1.2824 1.8587 <0.0001 1.3815 1.117 1.7088 0.0029
DRE 1.2906 0.9184 1.8136 0.1417 1.0953 0.7269 1.6505 0.6634
High grade prostate cancer
Age 2.6442 2.047 3.4155 <0.0001 2.1537 1.7027 2.7242 <0.0001
Prostate volume 0.6416 0.5329 0.7724 <0.0001 0.5777 0.4595 0.7262 <0.0001
No. of biopsy cores 0.7413 0.5654 0.9719 0.0952∗ 0.844 0.636 1.1201 0.1687
PSA 1.2826 1.0057 1.6358 0.067∗ 1.2544 0.9833 1.6002 0.1889
%free PSA 0.5645 0.4699 0.6781 <0.0001 0.5063 0.4175 0.614 <0.0001
BMI 1.0551 0.8776 1.2685 0.8195 1.0811 0.9053 1.2912 0.4994
Family history PCa 1.7416 1.2292 2.4676 0.0018 1.3653 0.9455 1.9714 0.0967
DRE 1.2037 0.6151 2.3558 0.5883 1.6935 0.9405 3.0493 0.0792
Erectile dysfxn
Age 0.7339 0.6295 0.8557 0.0004 0.7621 0.666 0.8722 0.0001
Sexually active 0.5096 0.3675 0.7067 0.0001 0.3664 0.2681 0.5006 <0.0001
Hx lack of libido 1.3311 1.038 1.707 0.0242 1.3472 1.0819 1.6775 0.0077
Hx impotence 1.2409 0.9787 1.5734 0.0747 0.9972 0.8107 1.2265 0.9785
Acute urianry retention
Age 0.8908 0.7196 1.1028 0.4819 0.8059 0.5185 1.2525 0.4953
Prostate volume 1.8827 1.4251 2.4873 <0.0001 0.9947 0.6244 1.5848 0.711
PSA 1.011 0.8024 1.2737 0.9935 1.2705 0.7303 2.2103 0.4152
IPSS 1.5953 1.1804 2.1558 0.0027 2.0617 1.0162 4.1826 0.0561∗
Qmax 0.5879 0.472 0.7323 <0.0001 0.9401 0.5678 1.5566 0.7829
Residual volume 1.2595 0.9105 1.7424 0.3255 1.5552 0.74 3.2685 0.0976
BPH-related surgery
Age 0.8127 0.6247 1.0572 0.0807 1.559 0.8902 2.7302 0.2985
Prostate volume 1.5691 1.1561 2.1297 0.0095 1.2977 0.7537 2.2343 0.6382
PSA 1.1172 0.8531 1.4629 0.2629 1.1834 0.6867 2.0396 0.6908
IPSS 2.5274 1.6817 3.7984 <0.0001 1.0011 0.5496 1.8234 0.0079∗
Qmax 0.5939 0.4581 0.7701 0.0004 0.7832 0.4732 1.2961 0.5844
Residual volume 1.1945 0.8151 1.7505 0.623 0.9939 0.4937 2.0008 0.7463
Gyn
Age 0.9581 0.6793 1.3514 0.9678 1.0843 0.8216 1.431 0.8477
BMI 1.3178 0.9245 1.8782 0.2171 1.173 0.9042 1.5216 0.1553
UTI
Qmax 0.7375 0.6153 0.8839 0.0023 1.0545 0.817 1.361 0.8655
Residual volume 1.243 0.9581 1.6125 0.2471 1.2778 0.9049 1.8044 0.2652
HGPIN
Age 1.4293 1.1525 1.7725 0.0008 1.1009 0.8335 1.454 0.5191
Prostate volume 0.8821 0.7065 1.1015 0.5214 0.8965 0.6763 1.1884 0.746
No. of biopsy cores 1.1212 0.8356 1.5043 0.4359 0.7871 0.5426 1.1416 0.4507
PSA 0.9833 0.7943 1.2174 0.9196 1.1428 0.849 1.5383 0.667
% free PSA 1.1113 0.9045 1.3654 0.5567 1.1635 0.8752 1.5468 0.5078
BMI 0.9732 0.8194 1.1559 0.3665 1.1077 0.8449 1.4523 0.2359
(Continued)
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Table 3 | Continued
Variables Placebo Dutasteride
HR Lower 0.95 Upper 0.95 P-value HR Lower 0.95 Upper 0.95 P-value
Family history PCa 1.1008 0.7477 1.6206 0.6266 1.1135 0.6828 1.8161 0.6665
DRE 1.1732 0.6183 2.2262 0.625 1.5201 0.7052 3.2768 0.2852
ASAP
Age 0.9748 0.786 1.2089 0.5177 1.0457 0.8091 1.3515 0.9228
Prostate volume 0.8217 0.6617 1.0203 0.0969 0.7806 0.6 1.0156 0.1721
No. of biopsy cores 1.0959 0.783 1.5337 0.7047 0.8367 0.6103 1.1471 0.0626
PSA 1.0578 0.8441 1.3255 0.8837 1.3181 0.9993 1.7387 0.1427
% free PSA 1.085 0.8719 1.3502 0.0485∗ 1.0896 0.8478 1.4005 0.4193
BMI 1.1344 0.9301 1.3835 0.3104 0.9405 0.7492 1.1808 0.7538
Family history PCa 1.1106 0.745 1.6554 0.6067 1.6653 1.1066 2.5061 0.0145
DRE 1.2115 0.6209 2.3639 0.5738 1.2553 0.5959 2.6445 0.5498
Gyn, gynecomastia; UTI, urinary tract infection, HGPIN, high grade prostatic intraepithelial neoplasia; ASAP, atypical small acinar proliferation. *The use of restricted
cubic splines may result in incongruency between significant p-values and hazard ratios that cross 1.0 as a result of the relaxed linearity assumptions.
Table 4 | Nomogram concordance indices.
Outcomes Placebo Dutasteride
PCa 0.61909 0.61205
HGPCa 0.6924 0.71333
ED 0.58557 0.59467
AUR 0.65849 0.61706
BPH-S 0.69534 0.59861
Gynecomastia 0.52166 0.52139
UTI 0.55017 0.51103
HGPIN 0.5321 0.47203
ASAP 0.48454 0.53215
PCa, prostate cancer; HGPCa, high grade prostate cancer; ED, erectile dysfunc-
tion; AUR, acute urinary retention; BPH-S, BPH related surgery; UTI, urinary tract
infection; HGPIN, high grade prostatic intraepithelial neoplasia; ASAP, atypical
small acinar proliferation.
The REDUCE metagram can theoretically provide estimates
of outcomes relevant to dutasteride treatment that are tailored
to a man at risk for developing PCa (i.e., older men with ele-
vated PSA and a history of previous negative biopsy). As an
online risk calculator, our metagram can be used by a physician
to enter patient-specific variables and generate a tabular presen-
tation of personalized risk estimates. The patient can then make a
truly informed decision regarding the appropriateness of chemo-
prevention based on the relative value he assigns to different
outcomes and health states. For example, a man who values sex-
ual function more than a chance of decreasing his cancer risk may
decline dutasteride treatment if his metagram-predicted risk of
ED is sufficiently high. On the other hand, a man who fears the
development of cancer above all else may opt for chemopreven-
tion even if his risk of PCa is minimal while his risks of side effects
are high.
In its current state, there are certain limitations to the use of
the REDUCE metagram in men considering chemoprevention.
First, it should be noted that dutasteride is not FDA-approved
for the indication of PCa risk reduction. This certainly does
not preclude the use of 5-ARIs in general as chemopreventive
agents, but patients must be adequately counseled regarding
their on-label and off-label uses. Second, some of the nomo-
grams, including those predicting the endpoints of HGPIN and
ASAP, generated predictions that were comparable to random
chance. This was related to the fact that those models completely
lacked predictive markers in both the placebo and dutasteride
cohorts. As a result, the overall cumulative incidence probabilities
of those endpoints were used in place of nomogram-generated
predictions. The application of group-level probabilities to the
individual patient is problematic because the study group may
not be representative of that particular patient. Furthermore,
the nomograms for BPH-related outcomes (e.g., AUR, BPH-
related surgery, and UTI) demonstrated reduced accuracy in the
dutasteride cohort, likely due to modification of the value of base-
line prostate-related markers by the drug itself. This shortcoming
could be addressed by the construction of nomograms that incor-
porate post-treatment values for markers like urinary flow rate or
prostate volume.
Third, the metagram does not predict for all potential adverse
effects of dutasteride, namely the composite event termed “car-
diac failure.” In the original study, investigators found a higher
incidence of cardiac failure (which included conditions such as
congestive heart failure, cardiac failure, acute cardiac failure,
ventricular failure, cardiopulmonary failure, and congestive car-
diomyopathy) among men who took dutasteride compared to
placebo (0.7 vs 0.4%, p = 0.03) (Andriole et al., 2010). Because
the original trial did not collect data on any clinical variables that
correlate with cardiovascular status, we were unable to build a
nomogram predicting cardiac failure and suggest that the cumu-
lative incidence rates of this endpoint from the REDUCE trial be
used to counsel patients and supplement themetagram-generated
predictions.
It should be noted that even among the nomograms that
demonstrated predictive accuracies greater than random chance,
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FIGURE 1 | (A) The REDUCE metagram as a user-friendly online risk calculator with “plug and play” functionality where the patient or physician can input
patient-specific variables to generate predictions; (B) Individualized patient outcomes are generated and presented in a clear and concise format.
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none predicted with 100% accuracy. As such, there is opportunity
to improve the predictive performance of the metagram by
improving its component nomograms. This can be achieved
through utilization of larger datasets, identification and incor-
poration of better predictive markers, standardization of data
collection methodology, and use of more sophisticated modeling
techniques.
Taken together, these considerations emphasize that nomo-
gram predictions must be interpreted as such; they are not perfect
and may not be applicable to all men at risk for PCa. By them-
selves, nomograms cannotmake treatment recommendations nor
can they take the place of patient counseling. The current role
of prediction models, like the REDUCE metagram, in clinical
practice is to provide patients with the best estimates of their
relevant individual outcomes, which, combined with physician
judgment and patient preference, can then form the basis for truly
informed decision-making regarding the utility of dutasteride
chemoprevention.
Using data from the REDUCE trial, we have created a com-
prehensive prediction tool that can simultaneously predict the
potential benefits and adverse effects of dutasteride treatment and
help determine the appropriateness of chemoprevention for men
at high risk for PCa. The metagram, in its current state, does not
predict all relevant outcomes with adequate accuracy but does
provide the framework for future research into the indications
and consequences of treatment with 5-ARIs.
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